Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Procter & Gamble Reports Fourth Quarter and Fiscal Year 2026 Results with Conference Call Disclosure

The Procter & Gamble Company disclosed its fourth quarter and full fiscal year 2026 financial results on July 29, 2026, through a press release and accompanying investor conference call. The company furnished informational presentation slides to the Securities and Exchange Commission as part of …

Nitish Kishor | 29 July 2026

Flowserve Reports Second-Quarter 2026 Results with Segment Performance Across Water, Energy and Distribution Divisions

Flowserve Corporation (NASDAQ: FELE) disclosed its second-quarter 2026 financial results in a regulatory filing dated July 29, 2026. The company operates three primary business segments—Water Systems, Energy Systems, and Distribution—serving infrastructure and industrial markets globally. The disclosure provides investors with detailed performance metrics across …

Vinay Lochav | 29 July 2026

Vicor Reports Second Quarter 2026 Results With Focus on Brick and Advanced Products Performance

Vicor Corporation, a NASDAQ-listed power conversion technology company, filed its quarterly report for the period ending June 30, 2026, disclosing operational and financial results for the second quarter. The filing provides detailed segment performance data across the company's Brick and Advanced Products lines, along …

Aakashdeep | 29 July 2026

Clean Harbors Reports Second Quarter 2026 Results With Dual Segment Performance

Clean Harbors, Inc. (NYSE: CLH) disclosed its second quarter 2026 financial results in a filing dated July 24, 2026, covering the period ended June 30, 2026. The company operates through two primary operating segments: Environmental Services and Safety-Kleen Sustainability Solutions. The disclosure provides investors …

Aakashdeep | 29 July 2026

Pool Corporation Reports Second Quarter 2026 Earnings Amid Net Sales Growth

Pool Corporation disclosed its financial results for the second quarter and first half of 2026 in a quarterly report filed with the Securities and Exchange Commission on July 29, 2026. The company reported net sales of $1.82 billion for the three-month period ended June …

Aakashdeep | 29 July 2026

Bremer Bank Acquisition Advances Financial Portfolio of OnBank, Signaling Strategic Growth

OnBank (NASDAQ: ONBPP) has disclosed details relating to its Bremer Bank acquisition in a quarterly filing dated July 29, 2026. The disclosure provides updated financial metrics and segmentation data reflecting the company's expanded lending and deposit portfolios across commercial, residential, and consumer segments. The …

Shwetambri Chauhan | 29 July 2026

LXP Industrial Trust Reports Second Quarter 2026 Financial Results and Supplemental Portfolio Metrics

LXP Industrial Trust disclosed its financial performance for the quarter ended June 30, 2026, through a press release and supplemental quarterly information released on July 29, 2026. The Maryland-based industrial real estate investment trust, which trades on the New York Stock Exchange, provided investors …

Aditi Sarkar | 29 July 2026

Johnson Controls Reports Third-Quarter Fiscal 2026 Results with Mixed Segment Performance Across Global Operations

Johnson Controls International plc disclosed its third-quarter fiscal 2026 financial results for the period ended June 30, 2026, revealing operational performance across its Products and Systems and Service segments. The company's filing, which encompasses operations spanning the Americas, Europe, Middle East and Africa (EMEA), …

Vinay Lochav | 29 July 2026

Lexington Realty Trust Reports Second Quarter 2026 Financial Results and Portfolio Updates

Lexington Realty Trust, a publicly traded real estate investment trust trading on NYSE under ticker LXP-PC, disclosed its second quarter 2026 financial performance and portfolio status in a quarterly update filed on July 29, 2026. The company reported results for the six-month period ending …

Vinay Lochav | 29 July 2026

Capricor Therapeutics Publishes HOPE-3 Phase 3 Results in The Lancet as FDA Issues Inspection Observations

Capricor Therapeutics announced on July 29, 2026, that The Lancet has published the final one-year results from its HOPE-3 Phase 3 clinical trial evaluating Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The publication followed independent peer review and coincided with an FDA …

Shwetambri Chauhan | 29 July 2026
Support

Hi! How can we help you today?

Loading…